How Met-Enkephalin in the Spinal Cord Helps Block Pain Signals
Spinal cord met-enkephalin release is a key part of how brain-administered opioids reduce pain perception in mice.
Quick Facts
What This Study Found
Intracerebroventricular etorphine increases met-enkephalin release in the spinal cord, and this spinal opioid mechanism accounts for a significant portion of the observed pain relief.
Key Numbers
How They Did This
In vivo mouse study using intracerebroventricular drug administration, tail-flick antinociception testing, spinal microdialysis to measure peptide release, and opioid receptor antagonists to identify receptor subtypes.
Why This Research Matters
Understanding how the brain's pain control system uses enkephalin peptides in the spinal cord could lead to more targeted pain therapies that work with the body's natural opioid systems rather than relying solely on external drugs.
The Bigger Picture
This research maps out a critical circuit in the body's natural pain defense: the brain activates descending pathways that release enkephalins in the spinal cord. This brain-to-spine opioid relay is fundamental to understanding how endogenous peptides modulate pain and could inform development of therapies targeting specific nodes in this pathway.
What This Study Doesn't Tell Us
Mouse model may not fully translate to human pain processing. Only one opioid agonist (etorphine) was tested. Spinal microdialysis provides regional but not cellular-level resolution of peptide release.
Questions This Raises
- ?Could targeting spinal enkephalin release specifically reduce the need for systemic opioid dosing?
- ?Do chronic pain conditions alter this brain-to-spine enkephalin relay?
- ?How do other endogenous opioid peptides (dynorphin, endorphin) interact with this spinal mechanism?
Trust & Context
- Key Stat:
- Spinal met-enkephalin release Significantly increased following brain opioid stimulation, contributing to pain relief via delta-opioid receptors
- Evidence Grade:
- Animal study with rigorous methodology including microdialysis and receptor-selective antagonists, but findings require human translation.
- Study Age:
- Published in 1997, this study established foundational knowledge about descending opioid pain pathways that remains relevant to current pain research.
- Original Title:
- [Met]enkephalin in the spinal cord is involved in the antinociception induced by intracerebroventricularly-administered etorphine in the mouse.
- Published In:
- Neuroscience, 80(2), 579-85 (1997)
- Authors:
- Xu, J Y, Tseng, L F(8)
- Database ID:
- RPEP-00440
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is met-enkephalin and what does it do?
Met-enkephalin is a naturally produced opioid peptide in the body that helps reduce pain. It works by binding to delta-opioid receptors, particularly in the spinal cord, as part of the body's built-in pain management system.
Why does this matter for pain treatment?
Understanding that the brain controls pain partly by triggering enkephalin release in the spinal cord could lead to treatments that enhance this natural mechanism, potentially offering pain relief with fewer side effects than traditional opioids.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00440APA
Xu, J Y; Tseng, L F. (1997). [Met]enkephalin in the spinal cord is involved in the antinociception induced by intracerebroventricularly-administered etorphine in the mouse.. Neuroscience, 80(2), 579-85.
MLA
Xu, J Y, et al. "[Met]enkephalin in the spinal cord is involved in the antinociception induced by intracerebroventricularly-administered etorphine in the mouse.." Neuroscience, 1997.
RethinkPeptides
RethinkPeptides Research Database. "[Met]enkephalin in the spinal cord is involved in the antino..." RPEP-00440. Retrieved from https://rethinkpeptides.com/research/xu-1997-metenkephalin-in-the-spinal
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.